Cannell & Spears’s GSK GSK Stock Holding History

Cannell & Spears’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,752	Closed	-$596K	–	129
2016 Q1	$596K	Buy	+11,752	New	+$585K	0.07%	73
2015 Q4	–	Sell	-5,755	Closed	-$277K	–	127
2015 Q3	$277K	Buy	5,755 +648	+13%	+$33.7K	0.03%	112
2015 Q2	$266K	Buy	5,107 +31	+0.6%	+$1.75K	0.03%	119
2015 Q1	$293K	Hold	5,076	–	–	0.04%	116
2014 Q4	$271K	Buy	+5,076	New	+$284K	0.03%	121

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cannell & Spears's GSK Position: Q2 2016 in Review

Cannell & Spears sold out of GSK (GSK) in Q2 2016, closing a stake of 11,752 shares — an estimated $596K sold.

Cannell & Spears first reported a position in GSK in Q4 2014 and held it in 5 quarters. The position peaked at $596K in Q1 2016. 741 funds tracked by Wall St. Rank hold GSK as of Q2 2016.

Cannell & Spears reported no remaining GSK position as of Q2 2016 after selling out during the quarter.
Cannell & Spears sold 11,752 GSK shares in Q2 2016, an estimated $596K.
Cannell & Spears first reported a position in GSK in Q4 2014 and held it in 5 quarters.
Cannell & Spears's GSK position peaked at $596K in Q1 2016.
741 funds tracked by Wall St. Rank held GSK as of Q2 2016.

Based on Cannell & Spears's 13F filing for Q2 2016, filed 10 Aug 2016.